바로가기
메인메뉴로 바로가기
콘텐츠 바로가기
하단메뉴로 바로가기
패밀리사이트 바로가기


진료과

  • 연세암병원-종양내과, 두경부암센터, 식도암센터, 폐암센터

전문진료분야

  • <종양내과> 폐암, 두경부암, 식도암, 항암약물치료, 신약치료

진료시간표

인터넷진료예약
의사시간표
진료시간
오전 암병원 암병원
오후 암병원 암병원

교육 및 임상 경력

  • 1990-1997  연세대학교  이과대학  생화학과
  • 1997-2001  연세대학교  의과대학  졸업
  • 2001-2002  서울  아산병원  인턴
  • 2002-2006  세브란스  병원  내과  전공의
  • 2006-2008  연세암센터  종양내과  임상강사
  • 2008-2009  연세대학교  의과대학  종양내과  전임강사
  • 2009-2013  연세대학교  의과대학  종양내과  조교수
  • 2013-2019  연세대학교  의과대학  종양내과  부교수
  • 2019-현  재  연세대학교  의과대학  종양내과  교수

학술관련경력

  • American Society of Clinical Oncology 회원
  • 대한 폐암학회 학술위원
  • 대한두경부암학회 학술위원
  • 대한항암요법연구회 두경부암 분과 간사
  • 대한항암요법연구회 폐암분과 위원
  • 저널 ‘Lung Cancer’지 편집위원
  • 내과학교실 학술위원회 위원
  • 내과학교실 연구위원회 간사
  • 다학제위원회 위원
  •  
  • [수상경력]
  • 2006 연세대학교 의과대학 내과학교실 연구부문 우수 전공의상
  • 2008 한국임상암학회 학술상
  • 2008 우현 학술상 수상
  • 2011 최우수 임상 교수상 수상
  • 2011 보원학술상 수상
  • 2017 보령학술상 우수상
  • 2017 연세대학교 의과대학 내과학교실 학술상 다작상
  • 2018 2017학년도 연구활동 국제협력상 부문 우수교수상
  • 2018 제 51회 유한의학상 우수상

주요 관심분야

  • 폐암 (폐종양) 최신 표적항암제, 면역 항암제, 신약 임상 연구
  • 식도암의 최신 표적항암제, 면역 항암제, 신약 임상 연구

학력사항

  • 1990-1997 연세대학교 이과대학 생화학과 학사
  • 1997-2001 연세대학교 의과대학 학사
  • 2003-2005 연세대학교 의과대학 석사
  • 2005-2011 연세대학교 의과대학 박사

논문

  • YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer. Yun J, Hong MH, Kim SY, Park CW, Kim S, Yun MR, Kang HN, Pyo KH, Lee SS, Koh JS, Song HJ, Kim DK, Lee YS, Oh SW, Choi S, Kim HR, Cho BC. Clin Cancer Res. 2019 Jan 22. doi: 10.1158/1078-0432.CCR-18-2906. [Epub ahead of print]
  • The Ratio of Peripheral Regulatory T Cells to Lox-1+ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer. Kim HR, Park SM, Seo SU, Jung I, Yoon HI, Gabrilovich DI, Cho BC, Seong SY, Ha SJ, Youn JI. Am J Respir Crit Care Med. 2019 Jan 15;199(2):243-246. doi: 10.1164/rccm.201808-1502LE.
  • Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck. Hong MH, Kim CG, Koh YW, Choi EC, Kim J, Yoon SO, Kim HR, Cho BC. Head Neck. 2018 Jan;40(1):55-62. doi: 10.1002/hed.24933. Epub 2017 Oct 16.
  • Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions. Soo RA, Lim SM, Syn NL, Teng R, Soong R, Mok TSK, Cho BC. Lung Cancer. 2018 Jan;115:12-20. doi: 10.1016/j.lungcan.2017.11.009. Epub 2017 Nov 13. Review.
  • ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma. Yun MR, Choi HM, Kang HN, Lee Y, Joo HS, Kim DH, Kim HR, Hong MH, Yoon SO, Cho BC. Oncogene. 2018 Jan 18;37(3):377-388. doi: 10.1038/onc.2017.339. Epub 2017 Sep 25.
  • Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types. Rhee JK, Jung YC, Kim KR, Yoo J, Kim J, Lee YJ, Ko YH, Lee HH, Cho BC, Kim TM. Cancer Immunol Res. 2018 Jan;6(1):87-97. doi: 10.1158/2326-6066.CIR-17-0201. Epub 2017 Nov 15.
  • A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal Cancer. Park YM, Keum KC, Kim HR, Cho BC, Kim DH, Cho NH, Kim SH. Ann Surg Oncol. 2018 Apr;25(4):864-871. doi: 10.1245/s10434-017-6208-5. Epub 2017 Oct 30.
  • Can We Prevent Resistance to Osimertinib? Combination or Sequential. Kim MH, Lim SM, Lee K, Soo RA, Cho BC. J Thorac Oncol. 2018 Jul;13(7):877-879. doi: 10.1016/j.jtho.2018.05.012
  • Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice. Park S, Ahn BC, Lim SW, Sun JM, Kim HR, Hong MH, Lee SH, Ahn JS, Park K, Choi Y, Cho BC, Ahn MJ. J Thorac Oncol. 2018 Sep;13(9):1373-1382. doi: 10.1016/j.jtho.2018.05.026. Epub 2018 Jun 5.
  • Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation. Kang HN, Choi JW, Shim HS, Kim J, Kim DJ, Lee CY, Hong MH, Park SY, Park AY, Shin EJ, Lee SY, Pyo KH, Yun MR, Choi HM, Lee SS, Kim SY, Lee H, Paik S, Cho BC, Lee JG, Kim HR. Lung Cancer. 2018 Oct;124:168-178. doi: 10.1016/j.lungcan.2018.08.008. Epub 2018 Aug 11.
  • Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset. Cho BC, Chewaskulyong B, Lee KH, Dechaphunkul A, Sriuranpong V, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cheng Y, Cho EK, Voon PJ, Lee JS, Mann H, Saggese M, Reungwetwattana T, Ramalingam SS, Ohe Y. J Thorac Oncol. 2019 Jan;14(1):99-106. doi: 10.1016/j.jtho.2018.09.004. Epub 2018 Sep 18.
  • Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models. Pyo KH, Kim JH, Lee JM, Kim SE, Cho JS, Lim SM, Cho BC. Lung Cancer. 2019 Jan;127:112-121. doi: 10.1016/j.lungcan.2018.11.035. Epub 2018 Nov 27.
  • Characterization of head and neck squamous cell carcinoma arising in young patients: Particular focus on molecular alteration and tumor immunity. Ryu HJ, Kim EK, Cho BC, Yoon SO. Head Neck. 2019 Jan;41(1):198-207. doi: 10.1002/hed.25507. Epub 2018 Dec 10.
  • ByoungChul Cho, Grace K. Dy, Ramaswamy Govindan, Dong-Wan Kim, Nathan A. Pennelle, Gerard Zalcman, Benjamin Besse, Joo-Hang Kim, GoekbenKoca, Prabhu Rajagopalan, Simon Langer, Matthias Ocker, Hendrik Nogai, Fabrice Barlesi. Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small cell lung cancer. Lung Cancer 123 (2018) 14?21.
  • Mi Ran Yun, Sun Min Lim, Seon-Kyu Kim, Hun Mi Choi, Kyoung Ho Pyo, SeongKeun Kim, Ji Min Lee, You Won Lee, Jae Woo Choi, Hye Ryun Kim, Min-Hee Hong, KeeokHaam, Nanhyung Huh, Jong-Hwan Kim, Yong Sung Kim, Hyo Sup Shim, Ross A Soo, Jin-Yuan Shih, James Chih-Hsin Yang, Mirang Kim, ByoungChul Cho. Enhancer remodeling and microRNA alterations associated with acquired resistance to ALK inhibitor. Cancer Res 2018 (In press).
  • Hong-Won Lee*, Byoungsan Choi*, Han Na Kang*, Hyunwoo Kim*, Ahrum Min, Minkwon Cha, Ji Young Ryu, Sangwoo Park, Jinyoung Sohn, Kihyuk Shin, Mi Ran Yun, JooYeun Han, Min Ju Shon, CherlhyunJeong, Junho Chung, Seung-Hyo Lee, Seock-Ah Im*, ByoungChul Cho*, Tae-Young Yoon* (*Co-coresponding). Profiling of protein?protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors. Nature Biomedical Engineering 2018 (In press).
  • Garassino MC, Cho BC, Kim JH, Mazieres J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA; ATLANTIC Investigators. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018 Mar 12.
  • Lim SM, Syn NL, Cho BC, Soo RA. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer Treat Rev. 2018 Feb 20;65:1-10.
  • Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018 Jan 1;29 (suppl 1):i10-i19.
  • Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018 Jan 11;378(2):113-125.
  • Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeno J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Ozguro?lu M; PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Nov 16;377(20):1919-1929
  • Sun Min Lim, Hye Ryun Kim, Jong-Seok Lee, Ki Hyeong Lee, Yun-Gyoo Lee, Young JooMin, Eun Kyung Cho, Sung Sook Lee, Bong-Seog Kim, Moon Young Choi, Hyo Sup Shim, Jin-Haeng Chung, Yoon La Choi, Min Jeong Lee, Maria Kim, Joo-Hang Kim, Siraj M. Ali, Myung-Ju Ahn, and ByoungChul Cho. Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non?Small-Cell Lung Cancer Harboring ROS1 Rearrangement. J Clin Oncol 2017 (e-pub) (Published with Editorial)
  • Hye Ryun Kim, Han Na Kang, Hyo Sup Shim, Jinna Kim, Jin Gu Lee, Chang Young Lee, Min Hee Hong, Sung-Moo Kim, Hwan Kim, Kyoung-Ho Pyo, Mi Ran Yun, Hye Ji Park, JooYeun Han, Hyun A Youn , Myung-Ju Ahn, Soonmyung Paik, Tae-Min Kim, and ByoungChul Cho. Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma. Ann Oncol 2017 (e-pub).
  • Han Sang Kim, Hwan Kim, Han Na Kang, Chae-Won Park, Sung-Moo Kim, Sang Joon Shin, Soo Hee Kim, Sang Kyum Kim, Eun Kyung Kim, Sang Gyun Kim, Zhenlong Zheng, Kee Yang Chung, Joel Greenbowe, Siraj M. Ali, Minkyu Jung, Tae-Min Kim, ByoungChul Cho. Oncogenic BRAF fusions in Mucosal Melanomas Activate the MAPK Pathway and are Sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. Oncogene 2017 (e-pub).
  • Kim HR, Ha SJ, Hong MH, Heo SJ, Koh YW, Choi EC, Kim EK, Pyo KH, Jung I, Seo D, Choi J, Cho BC (corresponding), Yoon SO. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Sci Rep 2016 (e-pub).
  • Kim HR, Jang JS, Sun JM, Ahn MJ, Kim DW, Jung I, Lee KH, Kim JH, Lee DH, Kim SW, Cho BC. A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01). Oncotarget 2016.
  • Kim SM, Kim H, Yun MR, Kang HN, Pyo KH, Park HJ, Lee JM, Choi HM, Ellinghaus P, Ocker M, Paik S, Kim HR, Cho BC. Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy. Oncogenesis 2016.
  • Lim SH, Sun JM, Choi YL, Kim HR, Ahn S, Lee JY, Lee SH, Ahn JS, Park K, Kim JH, Cho BC (corresponding), Ahn MJ. Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study. Cancer 2016.
  • Kyoung Ho Pyo, Sun Min Lim, Hye Ryun Kim, Young Hoon Sung, Mi Ran Yun, Sung-Moo Kim, Hwan Kim, Han Na Kang, Ji Min Lee, Sang Gyun Kim, Chae Won Park, Hyun Chang, Hyo Sup Shim, Han-Woong Lee, ByoungChul Cho. Establishment of a conditional transgenic mouse model recapitulating EML4-ALKpositive human non-small cell lung cancer. J Thorac Oncol 2016.
  • Sun Min Lim, Hye Ryun Kim, Siraj M. Ali, Joel R. Greenbowe, Hyo Sup Shim, Hyun Chang, Seungtaek Lim, Soonmyung Paik, ByoungChul Cho. Genomic Profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative. Oncotarget 2016 (In press).
  • Sung-Moo Kim, Hwan Kim, Min Hwan Kim, Jinyoung Sohn, Mi Ran Yun, Han Na Kang1, Chan Woo Kang, Hye Ryun Kim, Sun Min Lim, Yong WhaMoon, Soonmyung Paik, and ByoungChul Cho. EGFR-mediated activation of RIP-2 induces acquired resistance to GSK2118436 in BRAF V600E mutant non-small cell lung cancer. Mol Cancer Ther 2016.
  • Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. Sun Min Lim, Hyung Soon Park, Sangwoo Kim, Sora Kim, Siraj. M. Ali, Joel. R. Greenbowe, In Seok Yang, Nak-Jung Kwon, Jae Lyun Lee, Min-Hee Ryu, Jin-HeeAhn, Jeeyun Lee, Min Goo Lee, Hyo Song Kim, Hyunkki Kim, Hye Ryun Kim, Yong Wha Moon, Hyun Cheol Chung, Joo-Hang Kim, Yoon-Koo Kang and ByoungChul Cho. Oncotarget 2016.
  • Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J, Nakayama H, Havel L, Kondo H, Mitsudomi T, Zarogoulidis K, Gladkov OA, Udud K, Tada H, Hoffman H, Bugge A, Taylor P, Gonzalez EE, Liao ML, He J, Pujol JL, Louahed J, Debois M, Brichard V, Debruyne C, Therasse P, Altorki N. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2016
  • A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer. Heo SJ, Jung I, Lee CK, Kim JH, Lim SM, Moon YW, Shim HS, Jeong J, Kim JH, Kim HR, Cho BC. Cancer ChemotherPharmacol. 2016.
  • Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck. Huang KK, Jang KW, Kim S, Kim HS, Kim SM, Kwon HJ, Kim HR, Yun HJ, Ahn MJ, Park KU, Ramnarayanan K, McPherson JR, Zhang S, Rhee JK, Vettore AL, Das K, Ishimoto T, Kim JH, Koh YW, Kim SH, Choi EC, Teh BT, Rozen SG, Kim TM, Tan P, Cho BC. Sci Rep. 2016 Jan 21;6:19552.
  • Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy. Park HS, Lim SM, Shin HJ, Cho A, Shin JG, Lee MG, Kim HR, Kim JH, Cho BC. Pharmacogenet Genomics. 2016 Mar;26(3):116-125.
  • Lim SM, Kim HR, Cho EK, Min YJ, Ahn JS, Ahn MJ, Park K, Cho BC, Lee JH, Jeong HC, Kim EK, Kim JH. Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium). Oncotarget 2016.
  • Lim SM, Yoo JE, Lim KH, Meng Tai DW, Cho BC (corresponding), Park YN. Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma. Cancer Res Treat. 2016.
  • A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib. Cha YJ, Cho BC, Kim HR, Lee HJ, Shim HS. J Thorac Oncol. 2015 Dec 29.
  • Hyo Song Kim, Sung-Moo Kim, Hyunki Kim, Kyoung-Ho Pyo, Jong-Mu Sun, Myung-Ju Ahn, Keunchil Park, BhumsukKeam, Nak-Jung Kwon, Hwan Jung Yun, Hoon-Gu Kim, Ik-Joo Chung, Jong Seok Lee, Kyung Hee Lee, Dae Joon Kim, Chang Geol Lee, JinHur, Hyunsoo Chung, Jun Chul Park, Sung Kwan Shin, Sang Kil Lee, Hye Ryun Kim, Yong Wha Moon, Yong Chan Lee, Joo Hang Kim, Soonmyung Paik and ByoungChul Cho. Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma. Oncotarget. 2015 (In press).
  • Chan Woo Kang, Kang Won Jang, Jinyoung Sohn, Sung-Moo Kim, Kyoung-Ho Pyo1, Hwan Kim, Mi Ran Yun, Han Na Kang, Hye Ryun Kim, Sun Min Lim, Yong Wha Moon, Soonmyung Paik, Joo Hang Kim and ByoungChul Cho. Anti-tumor activity and acquired resistance mechanism of Dovitinib (TKI258) in RET rearranged lung adenocarcinoma. Mol Cancer Ther 2015 (In press).
  • Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, Ercan D, Matthews SE, Cantarini M, Barrett JC, Janne PA, Oxnard GR. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015 Jun;21(6):560-2.
  • Evans TL, Cho BC, Udud K, Fischer JR, Shepherd FA, Martinez P, Ramlau R, Syrigos KN, Shen L, Chadjaa M, Wolf M. Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy. J Thorac Oncol. 2015 Aug;10(8):1221-8.
  • Jin Ho Baek,, Jong-Mu Sun, Young Joo Min, Eun Kyung Cho, ByoungChul Cho, Joo-Hang Kim, Myung-Ju Ahn, Keunchil Park. Efficacy of EGFR tyrosine kinase inhibitors in patients withEGFR-mutated non-small cell lung cancer except both exon 19deletion and exon 21 L858R: A retrospective analysis in Korea. Lung Cancer. 2015 87: 148?154.
  • Nivolumab in NSCLC: latest evidence and clinical potential. Sundar R, Cho BC, Brahmer JR, Soo RA. Ther Adv Med Oncol (e-pub).
  • Kim HS, Kwon HJ, Jung I, Yun MR, Ahn MJ, Kang BW, Sun JM, Kim SB, Yoon DH, Park KU, Lee SH, Koh YW, Kim SH, Choi EC, Koo DH, Sohn JH, Kim B, Kwon NJ, Yun HJ, Lee MG, Lee JH, Kim TM, Kim HR, Kim JH, Paik S, Cho BC. Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck. Clin Cancer Res 2015 Feb 1;21(3):544-52.
  • Park K, Cho BC, Kim DW, Ahn MJ, Lee SY, Gernhardt D, Taylor I, Campbell AK, Zhang H, Giri N, Letrent SP, O'Connell J, Heo DS. Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial. J Thorac Oncol. 2014 Oct;9(10):1523-31.
  • Lim SM, Chung WY, Nam KH, Kang SW, Lim JY, Kim HG, Shin SH, Sun JM, Kim SG, Kim JH, Kang CW, Kim HR, Cho BC. An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer. Eur J Cancer. 2015 Aug;51(12):1588-95.
  • Keam B, Kim SB, Shin SH, Cho BC, Lee KW, Kim MK, Yun HJ, Lee SH, Yoon DH, Bang YJ. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer. 2015 Aug 1;121(15):2612-7.
  • Hyo Song Kim, Seung Eun Lee, Yoon Sung Bae, Dae Joon Kim, Chang Geol Lee, JinHur, Hyunsoo Chung, Jun Chul Park, Da Hyun Jung, Sung Kwan Shin, Sang Kil Lee, Yong Chan Lee, Hye Ryun Kim, Yong Wha Moon, Joo Hang Kim, Young Mog Shim, Susan S Jewell, Hyunki Kim, Yoon-La Choi, and ByoungChul Cho. Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated with Poor Survival in Patients With Resected Esophageal Squamous Cell Carcinoma. Oncotarget 2015 (e-pub).
  • Peter M Ellis, Frances A Shepherd, Michael Millward, Francesco Perrone, Lesley Seymour, Geoff rey Liu, Sophie Sun, ByoungChul Cho, Alessandro Morabito, Natasha B Leighl, Martin R Stockler, Christopher W Lee, RafalWierzbicki, Victor Cohen, Normand Blais, Randeep S Sangha, Adolfo G Favaretto, JinHyoung Kang, Ming-Sound Tsao, Carolyn F Wilson, Zelanna Goldberg, Keyue Ding, Glenwood D Goss*, Penelope Ann Bradbury. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small cell lung cancer (NCIC CTG BR.26): a double-blind, randomized, phase 3 trial. Lancet Oncol 2014 (e-pub).
  • Cha YJ, Lee JS, Kim HR, Lim SM, Cho BC, Lee CY, Shim HS. Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements. PLoS One 2014 Jul 24;9(7):e103333.
  • Sundar R, Soong R, Cho BC, Brahmer JR, Soo RA. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014 Aug;85(2):101-109.
  • Ahn MJ, Kim SW, Cho BC, Ahn JS, Lee DH, Sun JM, Massey D, Kim M, Shi Y, Park KPhase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR. Oncologist 2014 Jul;19(7):702-3.
  • Kim MH, Kim HR, Cho BC, Bae MK, Kim EY, Lee CY, Lee JS, Kang DR, Kim JH. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. Lung Cancer 2014 May;84(2):196-202.
  • Chang H, Shin SK, Cho BC, Lee CG, Kim CB, Kim DJ, Lee JG, Hur J, Lee CY, Bae MK, Kim HR, Lee SK, Park JC, Lee H, Kim HI, Chung H, Cha J, Lee YC, Kim JH. A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer. Cancer Chemother Pharmacol 2014 (e-pub).
  • Kim HR, Cho BC, Shim HS, Lim SM, Kim SK, Chang J, Kim DJ, Kim JH. Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma. Lung Cancer 2014 (e-pub).
  • Kim MH, Shim HS, Kang DR, Jung JY, Lee CY, Kim DJ, Lee JG, Bae MK, Kim HR, Lim SM, Kim EY, Park JS, Chung KY, Kim HJ, Kim JH, Cho BC. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma. Lung Cancer 2014 (e-pub).
  • Jin Woo Ahn, Han Sang Kim, Jung-Ki Yoon, Hoon Jang, Soo Min Han, SunghoEun, Hyo Sup Shim, Hyun Jung Kim, DaeJoon Kim, Jin Gu Lee, Chang Young Lee, Mi Kyung Bae, Kyung Young Chung, Ji Ye Jung, Eun Young Kim, Se Kyu Kim, Joon Chang, Hye Ryun Kim, Joo Hang Kim, Min Goo Lee, Cho BC (Co-corresponding author), Ji Hyun Lee, Duhee Bang. Identification of Somatic Mutations in EGFR/KRAS/ALK-negative Lung Adenocarcinoma in Never-Smokers. Genome Medicine 2014 (In press).
  • Maruja E. Lira, Yoon-La Choi, Sun Min Lim, Shibing Deng, Donghui Huang, Mark Ozeck, Joungho Han, Ji Yun Jeong, Hyo Sup Shim, Cho BC, Jhingook Kim, Myung-Ju Ahn, and Mao Mao. A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer. J Mol Diagn, 2014.
  • Kim HR, Lim SM, Kim HJ, Hwang SK, Park JK, Shin E, Bar MK, Ou S-H I, Wang J, Jewell SS, Kang DR, Soo RA, Haack H, Kim JH, Shim HS, Cho BC. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol 24: 2364?2370, 2013.
  • Modjtahedi H, Cho BC, Michel M, Solca F. A comprehensive review of preclinical profile of the ErbB family blocker afatinib in cancer. Naunyn-Schmiedeberg's Archives of Pharmacology (In press).
  • Lim SM, Chang H, Cho BC. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. Ann Oncol 2013 (e-pub).
  • A. D’cruz, T. Lin, A.K. Anand, D. Atmakusuma, M.J. Calaguas, I. Chitapanarux, B.C. Cho, B.C. Goh. Y Guo, W.S. Hsieh, C. Hu, D. Kwong, J.C. Lin, P.J. Lou, T. Lu, K. Prabhash, V. Sriuranpong, P. Tang, V.V. Vu, I. Wahid, K.K. Ang, A.T. Chan. Consensus recommendations for management of head and neck cancer in Asian countries: A review of international guidelines. Oral Oncol 2013
  • Lim S, Cho BC, Jung JY, Kim GM, Kim SH, Kim HR, Kim HS, Lim SM, Park JS, Lee JH, Kim D, Kim EY, Park MS, Kim YS, Kim SK, Chang J, Kim JH. Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated extensive stage small cell lung cancer. Lung Cancer 2013.
  • Kim SM, Hong YK, Solca F, Kim JH, Kim HJ, Cho BC. Enhancement of the anti-tumor activity of afatinib by inhibition of glycolysis in non-small cell lung cancer harboring the EGFR T790M mutation. Mol Cancer Ther 2013.
  • Kim HR, Kim DJ, Lee JG, Lee CY, Bae MK, Lee YJ, Kim SH, Soo RA, Ha SJ, Chung KY, Kim JH, Shim HS, Cho BC. Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated with Poor Survival and Cigarette Smoking Dosage in Resected Squamous Cell Lung Cancer Patients. J Clin Oncol 31(6):731-7, 2013.
  • Kim HS, Mitsudomi T, Cho BC. Personalized therapy On the Horizon for the Treatment of Lung Squamous Cell Carcinoma. Lung Cancer 2013 (Solicited review).
  • Lim SM, Kim HR, Shim HS, Soo RA, Cho BC. Role of fibroblast growth factor receptor as an emerging therapeutic target in lung squamous cell carcinoma. Future Oncol 2013 (Solicited Review).
  • Park HJ, Kusnadi A, Lee EJ, Kim WW, Cho BC, Lee IJ, Seong J, Ha SJ. Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. Cell Immunol. 2012 Jul;278(1-2):76-83.
  • Kim SH, Shim HS, Kim HR, Chang H, Kim GM, Yi JH, Kim JH, Cho BC. Phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 79(3):270-5, 2013.
  • Jung M, Cho BC, Lee CH, Park HS, Kang YA, Kim SK, Chang J, Kim DJ, Rha SY, Kim JH, Lee JH. EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI. Yonsei Med J. 2012 Nov 1;53(6):1128-35.
  • Devkota S, Sung YH, Choi J, Lee J, Ha NY, Kim H, Cho BC, Song J, Lee H. Ei24-deficiency attenuates Protein Kinase Ca signaling and Skin Carcinogenesis in mice. Journal of Biochemistry and Cell Biology 2012.
  • Chang H, KIM SH, Cho BC, YOON SH, KIM HR, Lee CG, Kim JH. Phase II Study of Cisplatin with Irinotecan as Induction Chemotherapy Followed by Chemoradiotherapy for Unresectable Stage III Non-small Cell Lung Cancer. Anticancer Res 32(8):3515-21 2012.
  • Soo RA, Kawaguchi T, Loh M, Ou SI, Shieh MP, Cho BC, Mok TS, Soong R. Differences in outcome and toxicity between Asian and Caucasian patients with lung cancer treated with systemic therapy. Future Oncol 8(4): 1-12, 2012
  • Hong S, Kang YA, Cho BC, Kim DJ. Elevated serum C-reactive protein as a prognostic marker in small cell lung cancer. Y Med J 1;53(1):111-7, 2012.
  • Kim GM, Kim YS, Kang YA, Lim ST, Kim JH, Kim SK, Cho BC. Efficacy and Toxicity of Belotecan for Relapsed or Refractory Small Cell Lung Cancer Patients. J Thorac Oncol 7: 731-736, 2012.
  • Kim HS, Kim HR, Kim HS, Kim GM, Kim JH, Cho BC. The Efficacy and Feasibility of S-1 and Cisplatin as First-line Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Cancer ChemotherPharmacol 2012 (e-pub).
  • Lee YJ, Shim HS, Cho BC. Gene copy number gain of Epidermal growth factor receptor is a predictive factor for EGFR tyrosine kinase inhibitor in squamous cell carcinoma of the lung. Clin Cancer Res 18(6): 1760-1768, 2012.
  • Kim SM, Kwon O, Hong YK, Sung JH, Kim JH, Yoon C, Solca F, Cho BC. Inhibition of IL-6R/JAK1/STAT3 signaling pathway increases the sensitivity to BIBW2992 in NSCLC cell lines with EGFR T790M. Mol Cancer Ther 2012.
  • Kim HR, Cho BC. The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences in KRAS Mutations in Korean Patients with Lung Adenocarcinoma. Yonsei Med Journal 2013.
  • Lim SM, Cho BC. Treatment outcome of patients with anaplastic thyroid cancer: A single center experience. Yonsei Medical Journal 2011.
  • Hong S, Cho BC, Choi HJ, Jung M, Lee SH, Park KS, Kim SK, Kim JH. Prognostic Factors in Small Cell Lung Cancer: A New Prognostic Index in Korean Patients. Oncology 16;79(3-4):293-300, 2011.
  • Kim HR, Shim HS, Chung J, Lee YJ, Jang MK, Ha SJ, Ross Soo, Kim JH, Cho BC. Distinct Clinical Features and Outcomes in Never-smokers with Non-Small Cell Lung Cancer who Harbor Mutations in Epidermal Growth Factor Receptor and KRAS, and ALK rearrangement. Cancer 2011.
  • Han H, Yoon J, Cho BC, Kim H, and Bang D. Multiple Target Loci Assembly Sequencing (mTAS). Analytical Biochemistry 2011;415:218-220.
  • Lee JG, Cho BC, Bae MK, Lee CY, Park IK, Kim DJ, Chung KY. Thoracoscopic Lobectomy Is Associated With Superior Compliance With Adjuvant Chemotherapy in Lung Cancer. Ann ThoracSurg2011;91:344-9.
  • Soo RA, Loh M, Mok TS, Ou I S-H, Cho BC, Yeo W-L, Tenen D, Soong R. Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer- results of a meta-analysis of randomised phase III trials. J Thorac Oncol 2011;6(6):1030-8.
  • Pei-JyeVoon, Cho BC, Wee-Lee Yeo, Ross A Soo. The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer. J Thorac Dis 2010; 3.
  • Lee YJ, Mok TS, Mitsudomi T, Cho BC. Lung cancer in Asian never smokers: Changes in mindset in the molecular era. Lung Cancer 2011 Apr;72(1):9-15.
  • Kim SM, Kim JS, Kim JH, Yun CO, Kim EM, Kim HK, Solca F, Choi SY, Cho BC. Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells. Cancer Letter 2010 296:150-9..
  • Lee YJ, Shim HS, Kang YA, Hong SJ, Kim HK, Kim H, Kim SK, Choi SH, Kim JH, Cho BC. Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology. 2010.
  • Cho BC, Kim JH, Soo RA, Yang CH. The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer. Yonsei Med J. 31;51(1):1-8, 2010.
  • Jeong j, Cho BC, Sohn JH, Choi HJ, Kim SH, Lee YJ, Jung MK, Shin SJ, Park MS, Kim SK, Chang J, Lim JH. Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: A phase II trial. Lung Cancer 2010 70:77-81.
  • Soo RA, Anderson BO, Cho BC, Yang CH, Liao M, Lim W, Goldstraw P, Mok TS. First line systemic treatment of advanced stage non-small cell lung cancer in Asia: Consensus statement from Asian Oncology Summit 2009. Lancet Oncol 10:1102-10, 2009.
  • Lee YJ, Cho BC (corresponding), Jee SH, Moon JW, Kim SK, Chang J, Chung KY, Park IK, Choi SH, Kim JH. Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never smoker patients with non-small cell lung cancer. J Clin Oncol 28:487-492, 2010.
  • Lee YJ, Choi HJ, Kim SK, Chang J, Moon JW, Park IK, Kim JH, Cho BC. Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with non-small cell lung cancer. Cancer 11:116(5);1336-1343, 2010.
  • Lee YJ, Lee CG, Cho BC, Kim GE, Choi HJ, Choi EC, Sohn JH, Kim JH. Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer. Head Neck. 32(2):235-43, 2010.
  • Lee YJ, Park IK, Park MS, Choi HJ, Chung KY, Kim SK, Chang J, Moon JW, Kim H, Choi SH, Kim JH, Cho BC. Activating mutations within the EGFR kinase domain: A molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 135(12):1647-54 2009.
  • Lee JE, Han SH, Cho BC, Park JT, Yoo TH, Kim BS, Park HC, Kang SW, Lee HY, Han DS, Ha SK, Choi KH.Cancer in patients on chronic dialysis in Korea. J Korean Med Sci. 2009 Jan;24 Suppl:S95-S101.
  • Cho BC, Keum KC, Shin SJ, Choi HJ, Lee YJ, Kim SH, Choi EC, Kim JH. Weekly Docetaxel in Patients with Platinum-refractory Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN). Cancer ChemotherPharmacol 65(1):27-32 2009.
  • Lee YJ, Cho A, Cho BC, Kim SK, Chang J, Moon JW, Park IK, Kim JH. High tumor metabolic activity as measured by FDG-PET is associated with poor prognosis in limited and extensive stage small cell lung. Clin Cancer Res 15(7):2426-32 2009.
  • Choi HJ, Cho BC, Shin SJ, Kim SH, Kim JH, Yoo NC. Brain metastases from hepatocellular carcinoma: prognostic factors and outcome : Brain metastasis from HCC. J Neurooncol, 2009.
  • Shin S, Kim KJ, Choi HJ, Kim H, Lee YJ, Kim JH, Cho BC. Complete response of recurrent squamous cell carcinoma of the lung: Does the dose matter? J Thorac Oncol 4:141-142, 2009.
  • Costa D, Nguyen K, Cho BC, Sequist L, Jackman D, Riely G, Yeap B, HalmosB, Kim JH, Janne P, Huberman M, Pao W, Tenen D, Kobayashi S. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 2008.
  • Lee JG, Cho BC, Bae MK, Lee CY, Park IK, Kim DJ, Chung KY. Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer. Lung Cancer 63, 106-110, 2009.
  • Cho BC, Kim BK, Choi HJ, Kim JH. A single institutional experience of surgically resected thymic epithelial tumors over 10 years: clinical outcomes and clinicopathologic features. Oncol Rep 2008.
  • Cho BC, Kim JH. In reply to correspondence (Costa DB, Schumer ST, Tenen DG, Kobayashi S. Differential Responses to Erlotinib in Epidermal Growth Factor Receptor(EGFR)-Mutated Lung Cancers With Acquired Resistance to Gefitinib Carrying the L747S or T790M Secondary Mutations. J Clin Oncol 26(7): 1182 ? 1184, 2008). J Clin Oncol 26(7):1184-1186, 2008.
  • Cho BC, Park MS, Kim SK, Chang J, Choi HJ, Kim JH. A phase II study of erlotinib treatment in advanced non-small cell lung cancer after failure of gefitinib. J Clin Oncol 25:2528-2533, 2007; Featured by Dr. P. A. Bunn Jr. Can Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Be Overcome by Different Small-Molecule Tyrosine Kinase Inhibitors? J Clin Oncol 25(18): 2504-2505, 2007.
  • Cho BC, Kim JH. Salvage use of erlotinib in advanced non-small cell lung cancer with acquired resistance to gefitinib: Is a clinical benefit still achievable? The American Journal Of Hematology/Oncology. 2007.
  • Cho BC, Kim SH, The number of lymph nodes with metastasis predicts recurrence free survival in patients who underwent resection of stage IIIAN2 and IIIB non-small-cell lung cancer after induction chemotherapy. Lung Cancer. 60:393-400, 2008.
  • Cho BC, Ahn JB, Seong J, Roh JK, Kim JH, Chung HC, Sohn JH, Kim NK. Chemoradiotherapy with or without Consolidation Chemotherapy using Cisplatin and 5-fluorouracil in Anal Squamous Cell Carcinoma: Long-term results in 31 patients. BMC Cancer. 2008
  • Cho BC, Jeung HC, Choi HJ, Rha SY, Hyung WJ, Cheong JH, Noh SH, Chung HC. Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: A 15-year experience at a single institute. J Surg Oncol 95:461-468, 2007.
  • Cho BC, Kim EH, Choi HJ, Kim JH, Roh JK, Chung HC, Ahn JB, Lee JD, Lee JT, Yoo NC, Sohn JH. A pilot study of trans-arterial injection of 166Holmium-Chitosan complex for treatment of small hepatocellular carcinoma. Yonsei Med J. 46:799-805, 2005
  • Cho BC, Kim NK, Lim BJ, Kang SO, Sohn JH, Roh JK, Choi ST, Kim SA, Park SE. A carcinoembryonic antigen-secreting adenocarcinoma arising in tailgut cyst: clinical implications of carcinoembryonic antigen. Yonsei Med J. 2005, 31;46:555-61.Cho BC, Kim JH, Kim CB, Sohn JH, Choi HJ, Lee YC, Ahn JB. Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer. Oncol Rep. 15:621-7, 2006.
  • Lee YS, Kim JH, Choi KJ, Choi IK, Kim H, Cho S, Cho BC, Yun CO. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an mmunocompetent murine model. Clin Cancer Res 12:5859-5868, 2006.
  • Jeung HC, Rha SY, Cho BC, Yoo NC, Roh JK, Roh WJ, Chung HC, Ahn JB. A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. Br J Cancer 95:1637-1641, 2006.
  • Choi HJ, Cho BC, Shin SJ, Cheon SH, Jung JY, Chang J, Kim SK, Sohn JH, Kim JH Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. Cancer ChemotherPharmacol. 2007
  • Shin SJ, Jeung HC, Ahn JB, Choi HJ, Cho BC, Rha SY, Yoo NC, Roh JK, Chung HC Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. Cancer ChemotherPharmacol 61:157-165, 2008.
  • Shin SJ, Ahn JB, Choi HJ, Cho BC, Jeung HC, Rha SY, Chung HC, Roh JK The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. Cancer ChemotherPharmacol 61:75-81, 2008.
  • Sohn JH, Choi HJ, Chang J, Kim SK, Lee CG, Chung KY, Kim DJ, Cho BC, Shin SJ, Moon YW, Kim JH A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer. Lung cancer 54:365-370, 2006.
  • Shin SS, Lee HY, Kim SH, Ahn JB, Choi HJ, Cho BC, Jeung HC, Rha SY, Chung HC, Pyo JY, Roh JK Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy. Acta Oncol 46:547-549, 2007.
  • Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset.
    JOURNAL OF THORACIC ONCOLOGY 14/1 :99-106,2019
  • Characterization of head and neck squamous cell carcinoma arising in young patients: Particular focus on molecular alteration and tumor immunity
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK 41/1 :198-207,2019
  • Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models
    LUNG CANCER 127/1 :112-121,2019
  • The Ratio of Peripheral Regulatory T Cells to Lox-1+ PMN-MDSC Predicts the Early Response to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer Patients
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 199/2 :243-246,2019
  • Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    LANCET ONCOLOGY 19/4 :521-536,2018
  • Profiling of protein?protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors.
    Nature biomedical engineering 2/ :239-253,2018
  • Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.
    ANNALS OF ONCOLOGY 29/Supple :10-19,2018
  • Osimertinib in Untreated EGFR-Mutated Advanced Non?Small-Cell Lung Cancer
    NEW ENGLAND JOURNAL OF MEDICINE 378/2 :113-125,2018
  • Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies.
    CANCER TREATMENT REVIEWS 65/ :1-10,2018
  • Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types.
    CANCER IMMUNOLOGY RESEARCH 6/1 :87-97,2018
  • ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
    ONCOGENE 37/3 :377-388,2018
  • Characteristics and Outcome of ROS1-Positive Non?Small Cell Lung Cancer Patients in Routine Clinical Practice
    JOURNAL OF THORACIC ONCOLOGY 13/9 :1,373-1,382,2018
  • Can We Prevent Resistance to Osimertinib? Combination or Sequential
    JOURNAL OF THORACIC ONCOLOGY 13/7 :877-879,2018
  • Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors.
    CANCER RESEARCH 78/12 :3,350-3,362,2018
  • Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer.
    LUNG CANCER 123/ :14-21,2018
  • Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
    LUNG CANCER 124/ :168-178,2018
  • A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal Cancer
    ANNALS OF SURGICAL ONCOLOGY 25/4 :864-871,2018
  • Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK 40/1 :55-62,2018
  • Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
    LUNG CANCER 115/ :12-20,2018
  • Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
    LANCET RESPIRATORY MEDICINE 5/11 :891-902,2017
  • Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization.
    ONCOTARGET 8/50 :87,234-87,243,2017
  • Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers
    LUNG CANCER 112/ :195-199,2017
  • Transoral robotic surgery-based therapy in patients with stage III-IV oropharyngeal squamous cell carcinoma
    ORAL ONCOLOGY 75/ :16-21,2017
  • Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
    NEW ENGLAND JOURNAL OF MEDICINE 377/20 :1,919-1,929,2017
  • Architectural patterns of p16 immunohistochemical expression associated with cancer immunity and prognosis of head and neck squamous cell carcinoma
    APMIS 125/11 :974-984,2017
  • Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis.
    ONCOTARGET 8/39 :65,111-65,122,2017
  • Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs
    LUNG CANCER 113/0 :106-114,2017
  • ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).
    JOURNAL OF THORACIC ONCOLOGY 12/9 :1,357-1,367,2017
  • A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) (vol 8, pg 15943, 2017)
    ONCOTARGET 8/9 :15,943-15,951,2017
  • Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
    ONCOGENE 36/23 :3,334-3,345,2017
  • Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer
    LUNG CANCER 111/ :79-83,2017
  • Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.
    JOURNAL OF CLINICAL ONCOLOGY 35/23 :2,613-2,618,2017
  • Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer
    LUNG CANCER 105/ :17-22,2017
  • Predictive factors of early distant brain failure after gamma knife radiosurgery alone in patients with brain metastases of nonsmall-cell lung cancer
    JOURNAL OF NEURO-ONCOLOGY 132/2 :333-340,2017
  • Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy
    CANCER RESEARCH AND TREATMENT 49/3 :669-677,2017
  • Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.
    ANNALS OF ONCOLOGY 28/6 :1,250-1,259,2017
  • Treatment options for EGFR mutant NSCLC with CNS involvement-Can patients BLOOM with the use of next generation EGFR TKIs?
    LUNG CANCER 108/ :29-37,2017
  • Impact of a planned dose interruption of dacomitinib in the treatmentof advanced non-small-cell lung cancer (ARCHER 1042)
    LUNG CANCER 106/ :76-82,2017
  • Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 79/5 :873-880,2017
  • Optimal dose and volume for postoperative radiotherapy in brain oligometastases from lung cancer: a retrospective study
    Radiation Oncology Journal 35/2 :153-162,2017
  • Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non?Small Cell Lung Cancer
    JOURNAL OF THORACIC ONCOLOGY 12/3 :491-500,2017
  • Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma.
    CANCER RESEARCH AND TREATMENT 49/01 :185-192,2017
  • Optimal Adjuvant Treatment for Curatively Resected Thoracic Esophageal Squamous Cell Carcinoma: A Radiotherapy Perspective
    CANCER RESEARCH AND TREATMENT 49/1 :168-177,2017
  • EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines
    MOLECULAR CANCER THERAPEUTICS 15/7 :1,627-1,636,2016
  • Clinical course of stage IV invasive mucinous adenocarcinoma of the lung
    LUNG CANCER 102/ :82-88,2016
  • PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
    SCIENTIFIC REPORTS 6/36956 :1-12,2016
  • Alteration status and prognostic value of MET in head and neck squamous cell carcinoma
    JOURNAL OF CANCER 7/15 :2,197-2,206,2016
  • Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK 38/Suppl :E1,653-E1,659,2016
  • Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus
    ONCOTARGET 7/9 :10,547-10,556,2016
  • A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 77/3 :539-548,2016
  • Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative
    ONCOTARGET 7/17 :24,172-24,178,2016
  • ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models
    LUNG CANCER 95/ :57-64,2016
  • Targeted sequencing identifies genetic alterations that confer Primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)
    ONCOTARGET 7/24 :36,311-36,320,2016
  • Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
    LANCET ONCOLOGY 17/6 :822-835,2016
  • Efficacy and Safety of Dovitinib in Pretreated Patients With Advanced Squamous Non-Small Cell Lung Cancer With FGFR1 Amplification: A Single-Arm, Phase 2 Study
    CANCER 122/19 :3,024-3,031,2016
  • Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.
    Oncogenesis 5/7 :e241-,2016
  • The Clinical Usefulness of 18F-Fluorodeoxyglucose Positron Emission Tomography (PET) to Predict Oncologic Outcomes and PET-Based Radiotherapeutic Considerations in Locally Advanced Nasopharyngeal Carcinoma
    CANCER RESEARCH AND TREATMENT 48/3 :928-941,2016
  • PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma
    ONCOTARGET 7/21 :30691-30701,2016
  • Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status
    LUNG CANCER 97/ :73-80,2016
  • A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib
    JOURNAL OF THORACIC ONCOLOGY 11/5 :e55-e58,2016
  • Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck
    SCIENTIFIC REPORTS 6/ :19552-,2016
  • A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806)
    LUNG CANCER 93/0 :1-8,2016
  • Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer
    LUNG CANCER 93/- :59-68,2016
  • Hippocampus-Sparing Whole-Brain Radiotherapy and Simultaneous Integrated Boost for Multiple Brain Metastases From Lung Adenocarcinoma: Early Response and Dosimetric Evaluation.
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT 15/1 :122-129,2016
  • Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy
    PHARMACOGENETICS AND GENOMICS 26/3 :116-125,2016
  • Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
    ONCOTARGET 6/42 :44971-44984,2015
  • Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells
    LUNG CANCER 90/2 :175-181,2015
  • Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma
    CANCER 121/15 :2612-2617,2015
  • Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy.
    JOURNAL OF THORACIC ONCOLOGY 10/8 :1221-1228,2015
  • Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma
    MOLECULAR CANCER THERAPEUTICS 14/10 :2238-2248,2015
  • Mutational landscapes of tongue carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance
    GENOME MEDICINE 7/98 :1-15,2015
  • Lack of ROS1 Gene Rearrangement in Glioblastoma Multiforme
    PLOS ONE 10/9 :e0137678-,2015
  • Nivolumab in NSCLC: latest evidence and clinical potential
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY 7/2 :85-96,2015
  • Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
    NATURE MEDICINE 21/6 :560-562,2015
  • An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer
    EUROPEAN JOURNAL OF CANCER 51/12 :1588-1595,2015
  • The regulation of glucose-6-phosphatase and phosphoenolpyruvate carboxykinase by autophagy in low-glycolytic hepatocellular carcinoma cells
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 463/2015 :440-446,2015
  • The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer
    LUNG CANCER 88/3 :325-331,2015
  • Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma
    ONCOTARGET 6/4 :2562-2572,2015
  • Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck
    CLINICAL CANCER RESEARCH 21/3 :544-552,2015
  • Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non-Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib A Phase I/II Trial
    JOURNAL OF THORACIC ONCOLOGY 9/10 :1523-1531,2014
  • Tumor MET expression profile predicts the outcome of non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors
    THORACIC CANCER 5/6 :517-524,2014
  • Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR
    ONCOLOGIST 19/7 :702-703,2014
  • Immunotherapy in the treatment of non-small cell lung cancer
    LUNG CANCER 85/2 :101-109,2014
  • Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements
    PLOS ONE 9/Issue 7 :e103333-,2014
  • Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
    GENOME MEDICINE 6/18 :1-10,2014
  • Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations
    LUNG CANCER 84/2 :196-202,2014
  • A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer
    JOURNAL OF MOLECULAR DIAGNOSTICS 16/2 :229-243,2014
  • Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma
    LUNG CANCER 83/3 :389-395,2014
  • A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 73/4 :665-671,2014
  • Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma
    LUNG CANCER 83/3 :374-382,2014
  • A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes
    ANNALS OF ONCOLOGY 24/12 :3089-3094,2013
  • Glycolysis Inhibition Sensitizes Non-Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation
    MOLECULAR CANCER THERAPEUTICS 12/10 :2145-2156,2013
  • Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung
    YONSEI MEDICAL JOURNAL 54/4 :854-864,2013
  • Personalized therapy on the horizon for squamous cell carcinoma of the lung
    LUNG CANCER 80/3 :249-255,2013
  • Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors
    SUPPORTIVE CARE IN CANCER 21/6 :1751-1759,2013
  • The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma
    ANNALS OF ONCOLOGY 24/9 :2364-2370,2013
  • Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer
    LUNG CANCER 80/3 :313-318,2013
  • The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences in KRAS Mutations in Korean Patients with Lung Adenocarcinoma
    YONSEI MEDICAL JOURNAL 54/4 :865-874,2013
  • Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma.
    FUTURE ONCOLOGY 9/3 :377-386,2013
  • Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer.
    JOURNAL OF CLINICAL ONCOLOGY 31/6 :731-737,2013
  • A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC)
    LUNG CANCER 79/3 :270-275,2013
  • The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY 27/1 :e53-e59,2013
  • The prognostic factors of resected non-small cell lung cancer with chest wall invasion
    WORLD JOURNAL OF SURGICAL ONCOLOGY 10/9 :1-7,2012
  • A Case of Synchronous Squamous Cell Carcinoma in the Esophagus and Stomach
    GUT AND LIVER 6/ :118-121,2012
  • Treatment of Epidermal Growth Factor Receptor Inhibitor-Induced Acneiform Eruption with Topical Recombinant Human Epidermal Growth Factor
    DERMATOLOGY 225/2 :135-140,2012
  • EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI
    YONSEI MEDICAL JOURNAL 53/6 :1128-1135,2012
  • Phase II Study of Cisplatin with Irinotecan as Induction Chemotherapy Followed by Chemoradiotherapy for Unresectable Stage III Non-small Cell Lung Cancer
    ANTICANCER RESEARCH 32/8 :3515-3521,2012
  • Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors
    CELLULAR IMMUNOLOGY 278/1-2 :76-83,2012
  • The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 70/4 :539-546,2012
  • Correlation Between 18F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Mutations in Advanced Lung Cancer
    Nuclear Medicine and Molecular Imaging 46/3 :169-175,2012
  • Activation of IL-6R/JAK1/STAT3 signaling induces De Novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation
    MOLECULAR CANCER THERAPEUTICS 11/10 :2254-2264,2012
  • Treatment Outcome of Patients with Anaplastic Thyroid Cancer: A Single Center Experience
    YONSEI MEDICAL JOURNAL 53/2 :352-357,2012
  • Ei24-deficiency attenuates protein kinase Cα signaling and skin carcinogenesis in mice
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY 44/11 :1887-1896,2012
  • Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients
    JOURNAL OF THORACIC ONCOLOGY 7/4 :731-736,2012
  • High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma
    CLINICAL CANCER RESEARCH 18/6 :1760-1768,2012
  • Elevated Serum C-Reactive Protein as a Prognostic Marker in Small Cell Lung Cancer
    YONSEI MEDICAL JOURNAL 53/1 :111-117,2012
  • Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement
    CANCER 118/3 :729-739,2012
  • Treatment of the Elderly When Cure is the Goal The Influence of Age on Treatment Selection and Efficacy for Stage III Non-small Cell Lung Cancer
    JOURNAL OF THORACIC ONCOLOGY 6/3 :537-544,2011
  • Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 2/ :685-693,2011
  • Ethnic Differences in Survival Outcome in Patients with Advanced Stage Non-small Cell Lung Cancer Results of a Meta-Analysis of Randomized Controlled Trials
    JOURNAL OF THORACIC ONCOLOGY 6/6 :1030-1038,2011
  • Multiple target loci assembly sequencing (mTAS)
    ANALYTICAL BIOCHEMISTRY 415/2 :218-220,2011
  • Lung cancer in never smokers: Change of a mindset in the molecular era
    LUNG CANCER 72/1 :9-15,2011
  • Thoracoscopic Lobectomy Is Associated With Superior Compliance With Adjuvant Chemotherapy in Lung Cancer
    ANNALS OF THORACIC SURGERY 91/2 :344-349,2011
  • Prognostic Factors in Small Cell Lung Cancer: A New Prognostic Index in Korean Patients
    Oncology 79/3-4 :293-300,2010
  • Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 136/12 :1937-1944,2010
  • Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: A phase II trial
    Lung Cancer 70/1 :77-81,2010
  • Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells.
    Cancer Letters 296/2 :150-159,2010
  • Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer
    Cancer 116/5 :1336-1343,2010
  • Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK 32/2 :235-243,2010
  • Impact of Environmental Tobacco Smoke on the Incidence of Mutations in Epidermal Growth Factor Receptor Gene in Never-Smoker Patients With Non-Small-Cell Lung Cancer
    JOURNAL OF CLINICAL ONCOLOGY 28/3 :487-492,2010
  • The Role of Monoclonal Antibody in Combination with First-Line Chemotherapy in Asian Patients with Advanced Non-Small Cell Lung Cancer
    YONSEI MEDICAL JOURNAL 51/1 :1-8,2010
  • Complete Response of Recurrent Squamous Cell Carcinoma of the Lung: Dose the Dose Matter?
    Journal Of Thoracic Oncology 4/1 :141-142,2009
  • Brain metastases from hepatocellular carcinoma: prognostic factors and outcome
    Journal Of Neuro-Oncology 91/3 :307-313,2009
  • First-line systemic treatment of advanced staege non-small-cell lung cancer in asia: consensus statement from the asian oncology summit 2009
    Lancet Oncology 10/ :1102-1110,2009
  • 비소세포성 폐암으로 수술 후 방사선치료가 시행된 N2병기 환자들에서 다발 부위 종격동 림프절 전이 여부에 따른 N2병기 구분의 임상적 의미
    Journal Of The Korean Society For Therapeutic Radiology And Oncology(대한방사선종양학회지) 27/3 :126-132,2009
  • Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 65/1 :27-32,2009
  • High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer
    Clinical Cancer Research 15/7 :2426-2432,2009
  • Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 135/12 :1647-1654,2009
  • Cancer in Patients on Chronic Dialysis in Korea
    Journal Of Korean Medical Science 24/ :S95-S101,2009
  • Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer
    Lung Cancer 63/ :106-110,2009
  • The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC
    Lung Cancer 60/3 :393-400,2008
  • Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy
    Cancer Chemotherapy And Pharmacology 61/ :309-313,2008
  • A single institutional experience of surgically resected thymic epithelial tumors over 10 years - Clinical outcomes and clinicopathologic features
    Oncology Reports 19/ :1525-1531,2008
  • Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: Long-term results in 31 patients
    Bmc Cancer 8/ :-,2008
  • The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer
    Cancer Chemotherapy And Pharmacology 61/ :75-81,2008
  • Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer
    Cancer Chemotherapy And Pharmacology 61/ :157-165,2008
  • Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: A 15-year experience at a single Institute
    JOURNAL OF SURGICAL ONCOLOGY 95/ :461-468,2007
  • Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib
    JOURNAL OF CLINICAL ONCOLOGY 25/18 :2528-2533,2007
  • Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy
    ACTA ONCOLOGICA 46/4 :547-549,2007
  • 유방암의 전신적 재발로 오인된 톡소플라스마증 1예
    대한내과학회지(korean Journal of medcine) 71/1 :108-113,2006
  • A pilot study of trans-arterial injection of 166Holmium-Chitosan complex for treatment of small hepatocellular carcinoma
    YONSEI MEDICAL JOURNAL 46/6 :799-805,2005
  • Subacute bacterial endocarditis associated with upper endoscopy
    YONSEI MEDICAL JOURNAL 45/5 :936-940,2004
  • Clinical and echocardiographic characteristics of pericardial effusion in patients who underwent echocardiographically guided pericardiocentesis: Yonsei Cardiovascular Center experience, 1993-2003
    YONSEI MEDICAL JOURNAL 45/3 :462-468,2004
  • Congenital absence of inferior vena cava as a rare cause of pulmonary thromboembolism
    YONSEI MEDICAL JOURNAL 45/ :947-951,2004
  • A case of lactic acidosis caused by stavudine in an AIDS patient
    The Korean Journal of Internal Medicine 19/1 :66-69,2004

조병철

진료철학
종양내과에서 폐암의 항암치료 (신약임상)이 전문분야로 진행성, 불응성 폐암의 내성 기전과 극복이 주요 관심 및 연구 분야입니다. 폐암 환자 뿐 아니라 그 가족까지도 세심히 살펴주려고 노력하고 있습니다. 항상 폐암 환자들에게 희망을 놓지 말고 적극적으로 치료하라고 권해 주고 싶습니다.

콘텐츠 처음으로 이동

네크워크 링크안내/사이트 정보